Market Place
Sourcing Support
New Data Show Influenza Vaccines Comparable For Adults 65+
18 Oct 2024 //
PR NEWSWIRE
CSL Seqirus Present Data At IDWeek 2024 On Flu Vaccination Needs
16 Oct 2024 //
PR NEWSWIRE
Europe taps CSL Seqirus to produce bird flu vaccines
12 Jun 2024 //
FIERCE PHARMA
CSL Seqirus Gets US Award For Pandemic Preparedness, Avian Flu Response
30 May 2024 //
PR NEWSWIRE
Cell-Based Quadrivalent Flu Vaccine Effective Over 3 Seasons
02 May 2024 //
PR NEWSWIRE
UK enlists CSL Seqirus for flu pandemic vaccine preparedness
27 Sep 2023 //
FIERCE PHARMA
Seqirus Begins Shipping Portfolio of Influenza Vaccines for 2022/23 U.S. Season
11 Jul 2022 //
PRNEWSWIRE
CDC Advisory Committee Recommends FLUAD QUADRIVALENT as Influenza Vaccine
22 Jun 2022 //
PRNEWSWIRE
Seqirus` Holly Springs Manufacturing Facility Designated by U.S. Govt
02 Jun 2022 //
PRNEWSWIRE
Sanofi petitions FDA over `misleading` label for rival flu vaccine
05 Mar 2022 //
ENDPTS
Seqirus, U.S. Government Renew Multi-Year Agreement for Influenza
25 Feb 2022 //
PRNEWSWIRE
Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation
23 Nov 2021 //
PRNEWSWIRE
Seqirus Presents New Real-World Evidence Supporting Effectiveness at ISIRV-WHO
19 Oct 2021 //
PRNEWSWIRE
FDA Approves Seqirus` Quadrivalent Influenza Vaccine, Expands Age Indication
15 Oct 2021 //
BIOSPACE
Sanofi, GSK and Seqirus prep for near-record flu shot sales
25 Aug 2021 //
FIERCEPHARMA
Seqirus reports record flu shot deliveries despite COVID woes
19 Aug 2021 //
FIERCEPHARMA
CDC launches disease forecasting center; J&J vaccine deserve booster info
18 Aug 2021 //
FIERCEPHARMA
Seqirus Presents New Ph3 Clinical Data
03 May 2021 //
PRNEWSWIRE
Seqirus Publishes New Real-World Evidence Supporting the Effectiveness
20 Apr 2021 //
PRNEWSWIRE
Seqirus Announces Health Canada Approval of Expanded Age Indication
18 Mar 2021 //
NEWSWIRE
Seqirus Announces U.S. FDA Approval of Expanded Age Indication of Its Cell
05 Mar 2021 //
PRNEWSWIRE
Seqirus Presents New Data at ESWI 2020 Demonstrating Safety and Immunogenicity
07 Dec 2020 //
PRNEWSWIRE
Seqirus Presents New Data at ESWI 2020 Demonstrating Safety and Immunogenicity
07 Dec 2020 //
PRNEWSWIRE
Seqirus plots $800M investment into major Australian shot plant
17 Nov 2020 //
FIERCE PHARMA
Seqirus Presents First-of-its-Kind Study on Cell-Based Quadrivalent Influenza
30 Oct 2020 //
PRNEWSWIRE
Seqirus Presents First-of-its-Kind Study Cell-Based Quadrivalent Vaccine (QIVc)
29 Oct 2020 //
PRNEWSWIRE
FDA approves first adjuvanted quadrivalent flu vaccine in over-65s
24 Feb 2020 //
APNEWS
Seqirus Announces USFDA Approval of Its Cell-Based Influenza A
03 Feb 2020 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.